» Articles » PMID: 23787145

Procalcitonin Decrease over 72 Hours in US Critical Care Units Predicts Fatal Outcome in Sepsis Patients

Overview
Journal Crit Care
Specialty Critical Care
Date 2013 Jun 22
PMID 23787145
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Close monitoring and repeated risk assessment of sepsis patients in the intensive care unit (ICU) is important for decisions regarding care intensification or early discharge to the ward. We studied whether considering plasma kinetics of procalcitonin, a biomarker of systemic bacterial infection, over the first 72 critical care hours improved mortality prognostication of septic patients from two US settings.

Methods: This retrospective analysis included consecutively treated eligible adults with a diagnosis of sepsis from critical care units in two independent institutions in Clearwater, FL and Chicago, IL. Cohorts were used for derivation or validation to study the association between procalcitonin change over the first 72 critical care hours and mortality.

Results: ICU/in-hospital mortality rates were 29.2%/31.8% in the derivation cohort (n=154) and 17.6%/29.4% in the validation cohort (n=102). In logistic regression analysis of both cohorts, procalcitonin change was strongly associated with ICU and in-hospital mortality independent of clinical risk scores (Acute Physiology, Age and Chronic Health Evaluation IV or Simplified Acute Physiology Score II), with area under the curve (AUC) from 0.67 to 0.71. When procalcitonin decreased by at least 80%, the negative predictive value for ICU/in-hospital mortality was 90%/90% in the derivation cohort, and 91%/79% in the validation cohort. When procalcitonin showed no decrease or increased, the respective positive predictive values were 48%/48% and 36%/52%.

Discussion: In septic patients, procalcitonin kinetics over the first 72 critical care hours provide prognostic information beyond that available from clinical risk scores. If these observations are confirmed, procalcitonin monitoring may assist physician decision-making regarding care intensification or early transfer from the ICU to the floor.

Citing Articles

Comparison of the accuracy of procalcitonin, neutrophil CD64, and C-reactive protein for the diagnosis and prognosis of septic patients after antibiotic therapy.

Zhu Q, Wang H, Chen L, Yu Y, Chen M Pract Lab Med. 2025; 43():e00444.

PMID: 39844927 PMC: 11751557. DOI: 10.1016/j.plabm.2024.e00444.


HNL Dimer in plasma is a unique and useful biomarker for the monitoring of antibiotic treatment in sepsis.

Venge P, Peterson C, Xu S, Larsson A, Johansson J, Tyden J PLoS One. 2024; 19(9):e0310987.

PMID: 39325799 PMC: 11426437. DOI: 10.1371/journal.pone.0310987.


Predicting Mortality in Sepsis: The Role of Dynamic Biomarker Changes and Clinical Scores-A Retrospective Cohort Study.

Varga N, Benea A, Suba M, Bota A, Avram C, Boru C Diagnostics (Basel). 2024; 14(17).

PMID: 39272757 PMC: 11393859. DOI: 10.3390/diagnostics14171973.


Diagnostic value of procalcitonin in infections in patients with malignant hematologic diseases.

Liu M, Tang Y, Xiao Y, Yan L, Xie L, Long X Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024; 49(5):721-729.

PMID: 39174886 PMC: 11341220. DOI: 10.11817/j.issn.1672-7347.2024.230589.


Therapeutic Drug Monitoring and Biomarkers; towards Better Dosing of Antimicrobial Therapy.

Wehbe E, Patanwala A, Lu C, Kim H, Stocker S, Alffenaar J Pharmaceutics. 2024; 16(5).

PMID: 38794338 PMC: 11125587. DOI: 10.3390/pharmaceutics16050677.


References
1.
Schuetz P, Christ-Crain M, Huber A, Muller B . Long-term stability of procalcitonin in frozen samples and comparison of Kryptor and VIDAS automated immunoassays. Clin Biochem. 2009; 43(3):341-4. DOI: 10.1016/j.clinbiochem.2009.08.029. View

2.
Coelho L, Salluh J, Soares M, Bozza F, Verdeal J, Castro-Faria-Neto H . Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study. Crit Care. 2012; 16(2):R53. PMC: 3681380. DOI: 10.1186/cc11291. View

3.
Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay M, Huber P, Tamm M . Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004; 363(9409):600-7. DOI: 10.1016/S0140-6736(04)15591-8. View

4.
Schuetz P, Mueller B . To escalate or to de-escalte--that is the question. Crit Care Med. 2011; 39(11):2590. DOI: 10.1097/CCM.0b013e31822a5ddf. View

5.
Theodorou V, Papaioannou V, Tripsianis G, Panopoulou M, Christophoridis E, Kouliatsis G . Procalcitonin and procalcitonin kinetics for diagnosis and prognosis of intravascular catheter-related bloodstream infections in selected critically ill patients: a prospective observational study. BMC Infect Dis. 2012; 12:247. PMC: 3502591. DOI: 10.1186/1471-2334-12-247. View